Validation Of Tidal/End -Tidal CO2 in ALS (VOTECO2ALS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03764384|
Recruitment Status : Active, not recruiting
First Posted : December 5, 2018
Last Update Posted : January 18, 2020
|Condition or disease|
|Motor Neuron Disease Amyotrophic Lateral Sclerosis|
This is a prospective, observational study of patients attending Royal Papworth Hospital's weekly MND clinic. If a patient decides to participate in the study, they will continue to receive all normal care. Researchers will ask permission to review the results of any medical investigations and tests previously undertaken, by looking in medical records and will collect new data prospectively. There will be two groups of patients recruited:
A).Hospital Questionnaire Monitoring Group (12 months) for up to 200 patients who will:
i) Have four routine hospital based assessments (every 3 months, standard care) ii) Above usual care: completion of the ALSFRS-R questionnaire at each clinic (4 in total. The ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Score-Revised) measures range of difficulties that people with MND can have in their daily lives. The results from this questionnaire help to measure the severity of MND symptoms, and how fast the disease is progressing. B). Home Device Monitoring Group (12-24 months) for 30 patients These participants patient will be given a portable monitoring device (called the N-Tidal C) to record their breathing pattern in clinic and at home and have: i) Four to six routine hospital based assessments (every 3 months, standard care). At the discretion of the investigator this may be at each clinic visit up to a total of 24 months ii) Completion of an ALSFRS-R symptom questionnaire at each visit (4-6 in total). At the discretion of the investigator this may be at each clinic visit up to a total of 24 months iii) Telephone consultation 2 weeks after commencing home monitoring to validate correct and safe use of the device (1 in total) iv) Completion of a supervised N-Tidal C breath record at each clinic visit (4 to 6 total). At the discretion of the investigator this may be at each clinic visit up to a total of 24 months v) Completion of a weekly symptom diary (up to 52 in total). At the discretion of the investigator this may continue up to 24 months vi) Home monitoring with N-Tidal C for 75 seconds, up to 3 times per day (up to study finish). SA 02 introduced an additional modified breath holding manoeuvre for home monitoring patients in clinic.
The range of 4 to 6 assessments covers the eventuality that participants may start in group A and transfer to group B as their condition changes. This will be determined by the treating doctor and will be based upon their lung function, limb weakness and whether they (or a carer) are able to use the device. During the home monitoring trial, data collected by the N-Tidal C device will be downloaded at each clinic visit, to check that the device is correctly recording data. Researchers will not be able to analyse the data collected by the device.
Only the information obtained from the standard measurements (standard care) will be used to decide when a patient needs help with their breathing at night time by starting a ventilator. A patient participating in the Home Monitoring Group will continue to use their N-Tidal C device to record their daytime breathing up to 3 times per day, after they start using a ventilator.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||An Observational Study in People With Amyotrophic Lateral Sclerosis to Validate Tidal /End-Tidal CO2, Measured by the N-Tidal C™ Against Directly Measured PaCO2 and to Determine the Ease of Home Use of the Device|
|Actual Study Start Date :||August 20, 2018|
|Estimated Primary Completion Date :||June 4, 2020|
|Estimated Study Completion Date :||June 4, 2020|
Hospital Monitoring Group - ALSFRS-R cohort
All patients will be first recruited to this cohort unless at their first visit the investigator deems them eligible for the Home Monitoring Device Group. At the initial screening visit, all patients recruited into the study will undergo routine assessments according to the existing MND protocol, and additionally complete the ALSFRS-R symptom-based assessment questionnaire by interview with the study researchers (with assistance from spouse, family member or carer if required). Patients will continue to complete the ALSFRS-R symptom-based questionnaire at each clinic attendance.
Home Monitoring Cohort
If eligible patients will use the N Tidal CTM, up to 3 times a day (morning, midday and evening) throughout the home monitoring period until the final outpatient clinic visit.
In addition subjects will complete a weekly diary symptom monitoring diary which asks them about their respiratory symptoms, GP attendances, respiratory infections. Patients routine standard of care assessments will also be documented according to the protocol as well as completing the ALSFRS-R at each visit.
- The primary outcome of interest is the degree of agreement between end tidal CO2 measured by the N-Tidal CTM device and PaCO2 from arterial blood gas analysis. [ Time Frame: At each clinic visit through to study completion up to 24 months ]Arterial blood gas (measured in kPa) will be compared to the end tidal CO2 (kPa) measured from the N-Tidal CTM device. The measurements will be taken within 20 minutes of each other. The paired CO2 measures from N-Tidal CTM device and from ABG will be assessed for agreement. The results will be displayed graphically using a Bland Altman Plot and the mean difference, the standard deviation of the mean difference and confidence intervals for 95% limits of agreement will be reported.
- Identify when an MND patient requires additional support with their breathing, in the form of starting NIV as derived from the CO2 measurement (kPA) and Respiratory Rate (RR) per minute from the N-Tidal CTM device. [ Time Frame: At each clinic visit through to study completion up to 24 months ]The waveforms taken from the N-Tidal CTM device will be analysed to give an end tidal CO2 (kPa) value and the mean and standard deviation of Respiratory rate per minute. Assuming there is an acceptable level of agreement between the two methods of measuring CO2 the data will be reviewed to establish if the end tidal measurement identified the onset of ventilatory failure before the clinic visit where it was confirmed on an arterial blood gas. After inspection of the data a judgement will be made on whether the correct measure is an individual result >6kPa or whether 2 or more consecutive measures >6 kPa would be the most reliable measure to conclude that ventilatory failure has now developed. For those participants who develop a PaCO2 > 6 kPa, the amount of time by which this predates the confirmatory blood gas will be reported in weeks.
- Identify when an MND patient develops a treatable respiratory condition, such as an infection as derived from the CO2 measurement (kPA) and Respiratory Rate (RR) per minute from the N-Tidal CTM device.. [ Time Frame: At each clinic visit through to study completion up to 24 months ]The mean end tidal CO2 (kPa) and the mean RR taken from the N-Tidal CTM device on the day before and the day of an identified respiratory event (from the symptom diary) will be examined to see if there is a reproducible change in the signal that might indicate that a respiratory event has occurred assuming in the future that the device will be monitored remotely.
- Any adverse events (AEs) reported during performing the study procedures [ Time Frame: At each clinic visit through to study completion up to 24 months ]Safety outcome
- Any adverse device events (ADEs [ Time Frame: At each clinic visit through to study completion up to 24 months ]Safety outcome
- Visual analogue scale (VAS) to record 'ease of use' of the N-Tidal C™ device during the study and at study completion [ Time Frame: At each clinic visit through to study completion up to 24 months ]Patient outcome measure. VOTECO2ALS 'Ease of use Questionnaire' has been devised by the study team to gather patient feedback on their participation in the trial and how they have found using the device. The scale has a series of statements and patients are asked to choose one of the following 5 options; disagree strongly, disagree, neither agree or disagree, agree, agree strongly. A 'disagree' response would represent a poor outcome in regards to the study design and device use where as an 'agree' option would be a better outcome in regards to the study design and usability of the device. The feedback from the subjects on ease of use will be examined for common themes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03764384
|Royal Papworth NHS Foundation Trust|
|Papworth Everard, Cambridge, United Kingdom, CB23 3RE|
|Principal Investigator:||Ian E Smith, MA MD F.R.C.P||Royal Papworth NHS Hospital|